2011 ASH Program Book - American Society of Hypertension

MAY 24
Sessions
Tuesday Morning
8:15 AM – 9:30 AM • West Ballroom • Third Floor
Late-Breaking Clinical Trials
Co-Chairs: George L. Bakris, MD, FASH, Chicago, IL and
William B. White, MD, FASH, Farmington, CT
8:15 AM LB-OR-01: Evaluation of Cardiovascular Effects in
Three Double-Blind, Placebo-Controlled Clinical
Trials with Controlled-Release Phentermine/
Topiramate
Suzanne Oparil†, 1 Wesley Day, 2 Charles Bowden. 2
1 University of Alabama, Birmingham, AL, US; 2 Vivus,
Mountain View, CA, US.
8:30 AM LB-OR-02: Longterm (3 – 5 Months) Spaceflight
Promotes a Sustained Decrease in Blood Pressure
and Systemic Vascular Resistance in Astronauts
Peter Norsk, 1 Ali Asmar, 1 Niels Juel Christensen. 2
1 University of Copenhagen, Copenhagen, DK; 2 Herlev
University Hospital, Herlev, DK.
8:45 AM LB-OR-03: Azilsartan Medoxomil Plus
Chlorthalidone Reduces BP More Effectively
Than Olmesartan Plus HCTZ in Stage 2 Systolic
Hypertension
William C. Cushman†, 1 George Bakris, 2 William B.
White, 3 Michael Weber, 4 Domenic Sica, 5 Andrew
Roberts, 6 Eric Lloyd, 6 Stuart Kupfer. 6 1 University of
TN College of Medicine, US; 2 U of Chicago Pritzker
School of Medicine, US; 3 U of CT School of Medicine,
US; 4 New York, NY, US; 5 VA Commonwealth U Health
System, US; 6 Takeda Global Research & Development,
US.
9:00 AM LB-OR-04: Common Blood Pressure Genetic
Variants and Their Relations to Hypertension,
Target-Organ Damage, and Cardiovascular Disease
Risk: The International Collaboration for Blood
Pressure Genome-Wide Association Studies (ICBP)
Georg Ehret, 1 Patricia Munroe, 4 Christopher Newton-
Cheh, 5 Kenneth Rice, 3 Cornelia van Duin, 6 Aravinda
Chakravarti, 1 Daniel Levy, 2 Mark Caulfield, 4 Toby
Johnson. 4 1 Johns Hopkins, Baltimore, MD, US;
2 NHLBI, Framingham, MA, US; 3 University of
Washington, Seattle, WA, US; 4 London School of
Medicine, London, GB; 5 Broad Institute, Cambridge,
MA, US; 6 The Rotterdam Study, Rotterdam, NL.
continued…
78